Phase 2b RCT | Rituximab vs. IV cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease.

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial – The Lancet Respiratory Medicine

Commentaries:

RECITAL: Rituximab represents alternative to cyclophosphamide for CTD-ILD – medwire News

CTD-ILD: Rituximab ‘a Reasonable Alternative to Cyclophosphamide’ – Medscape (free registration required)

Commentary on Twitter

https://twitter.com/LancetRespirMed/status/1592057243075112960